Impact of gadoxetic acid (Gd-EOB-DTPA)-enhanced magnetic resonance on the non-invasive diagnosis of small hepatocellular carcinoma: A prospective study

Alimentary Pharmacology and Therapeutics

Volumn 37, Issue 3, 2013, Pages 355-363

  Granito, A ^a   Galassi, M ^a   Piscaglia, F ^a   Romanini, L ^b   Lucidi, V ^a   Renzulli, M ^a   Borghi, A ^a   Grazioli, L ^b   Golfieri, R ^a   Bolondi, L ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b Diagnostic Imaging Department   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GADOXETIC ACID; SONOVUE;

ADULT; AGED; CANCER CLASSIFICATION; CANCER SIZE; CLINICAL ARTICLE; CLINICAL FEATURE; COHORT ANALYSIS; COMPUTED TOMOGRAPHY SCANNER; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; ECHOGRAPHY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER NODULE; MALE; MULTIDETECTOR COMPUTED TOMOGRAPHY; NON INVASIVE MEASUREMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; REVIEW; SENSITIVITY AND SPECIFICITY; SPIRAL COMPUTER ASSISTED TOMOGRAPHY; TUMOR VASCULARIZATION; ULTRASOUND SCANNER;

AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; CONTRAST MEDIA; FEMALE; GADOLINIUM DTPA; HUMANS; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 84871987522     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12166     Document Type: Review

References (34)

1. Sala M, Llovet JM, Vilana R, et al,. Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma. Hepatology 2004; 40: 1352-60. (Pubitemid 39657009)
2. Lopez PM, Villanueva A, Llovet JM,. Systematic review: evidence-based management of hepatocellular carcinoma-an updated analysis of randomized controlled trials. Aliment Pharmacol Ther 2006; 23: 1535-47. (Pubitemid 43727460)
3. Forner A, Vilana R, Ayuso C, et al,. Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology 2008; 47: 97-104. (Pubitemid 351171046)
4. Sangiovanni A, Manini MA, Iavarone M, et al,. The diagnostic and economic impact of contrast imaging techniques in the diagnosis of small hepatocellular carcinoma in cirrhosis. Gut 2010; 59: 638-44.
5. Kudo M,. Multistep human hepatocarcinogenesis: correlation of imaging with pathology. J Gastroenterol 2009; 44 (Suppl. 19): 112-8.
6. Bolondi L, Gaiani S, Celli N, et al,. Characterization of small nodules in cirrhosis by assessment of vascularity: the problem of hypovascular hepatocellular carcinoma. Hepatology 2005; 42: 27-34. (Pubitemid 40911308)
7. Leoni S, Piscaglia F, Golfieri R, et al,. The impact of vascular and nonvascular findings on the noninvasive diagnosis of small hepatocellular carcinoma based on the EASL and AASLD criteria. Am J Gastroenterol 2010; 105: 599-609.
8. Wanless IR,. Liver biopsy in the diagnosis of hepatocellular carcinoma. Clin Liver Dis 2005; 9: 281-5, vii.
9. Fidler J, Hough D,. Hepatocyte-specific magnetic resonance imaging contrast agents. Hepatology 2011; 53: 678-82.
10. Seale MK, Catalano OA, Saini S, Hahn PF, Sahani DV,. Hepatobiliary- specific MR contrast agents: role in imaging the liver and biliary tree. Radiographics 2009; 29: 1725-48.
11. Ringe KI, Husarik DB, Sirlin CB, Merkle EM,. Gadoxetate disodium-enhanced MRI of the liver: part 1, protocol optimization and lesion appearance in the noncirrhotic liver. AJR Am J Roentgenol 2010; 195: 13-28.
12. Cruite I, Schroeder M, Merkle EM, Sirlin CB,. Gadoxetate disodium-enhanced MRI of the liver: part 2, protocol optimization and lesion appearance in the cirrhotic liver. AJR Am J Roentgenol 2010; 195: 29-41.
13. Zech CJ, Reiser MF, Herrmann KA,. Imaging of hepatocellular carcinoma by computed tomography and magnetic resonance imaging: state of the art. Dig Dis 2009; 27: 114-24.
14. Lee JM, Zech CJ, Bolondi L, et al,. Consensus report of the 4th International Forum for Gadolinium-Ethoxybenzyl-Diethylenetriamine Pentaacetic Acid Magnetic Resonance Imaging. Korean J Radiol 2011; 12: 403-15.
15. Becker-Weidman DJ, Kalb B, Sharma P, et al,. Hepatocellular carcinoma lesion characterization: single-institution clinical performance review of multiphase gadolinium-enhanced MR imaging-comparison to prior same-center results after MR systems improvements. Radiology 2011; 261: 824-33.
16. Motosugi U, Ichikawa T, Sou H, et al,. Distinguishing hypervascular pseudolesions of the liver from hypervascular hepatocellular carcinomas with gadoxetic acid-enhanced MR imaging. Radiology 2010; 256: 151-8.
17. Kobayashi S, Matsui O, Gabata T, et al,. Relationship between signal intensity on hepatobiliary phase of gadolinium ethoxybenzyl diethylenetriaminepentaacetic acid (Gd-EOB-DTPA)-enhanced MR imaging and prognosis of borderline lesions of hepatocellular carcinoma. Eur J Radiol 2012; 81: 3002-9.
18. Bruix J, Sherman M,. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-36. (Pubitemid 43112690)
19. Golfieri R, Renzulli M, Lucidi V, Corcioni B, Trevisani F, Bolondi L,. Contribution of the hepatobiliary phase of Gd-EOB-DTPA-enhanced MRI to Dynamic MRI in the detection of hypovascular small (≤2 cm) HCC in cirrhosis. Eur Radiol 2011; 21: 1233-42.
20. Terminology of nodular hepatocellular lesions. International Working Party. Hepatology 1995; 22: 983-93.
21. Sherman M,. The radiological diagnosis of hepatocellular carcinoma. Am J Gastroenterol 2010; 105: 610-2.
22. Khalili K, Kim TK, Jang HJ, et al,. Optimization of imaging diagnosis of 1-2 cm hepatocellular carcinoma: an analysis of diagnostic performance and resource utilization. J Hepatol 2011 Apr; 54: 723-8.
23. van Montfoort JE, Stieger B, Meijer DK, Weinmann HJ, Meier PJ, Fattinger KE,. Hepatic uptake of the magnetic resonance imaging contrast agent gadoxetate by the organic anion transporting polypeptide Oatp1. J Pharmacol Exp Ther 1999; 290: 153-7. (Pubitemid 29302315)
24. Lorusso V, Pascolo L, Fernetti C, Visigalli M, Anelli P, Tiribelli C,. In vitro and in vivo hepatic transport of the magnetic resonance imaging contrast agent B22956/1: role of MRP proteins. Biochem Biophys Res Commun 2002; 293: 100-5. (Pubitemid 34694176)
25. Tsuda N, Kato N, Murayama C, Narazaki M, Yokawa T,. Potential for differential diagnosis with gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging in experimental hepatic tumors. Invest Radiol 2004; 39: 80-8. (Pubitemid 38140538)
26. Huppertz A, Haraida S, Kraus A, et al,. Enhancement of focal liver lesions at gadoxetic acid-enhanced MR imaging: correlation with histopathologic findings and spiral CT-initial observations. Radiology 2005; 234: 468-78. (Pubitemid 40139918)
27. Saito K, Kotake F, Ito N, et al,. Gd-EOB-DTPA enhanced MRI for hepatocellular carcinoma: quantitative evaluation of tumor enhancement in hepatobiliary phase. Magn Reson Med Sci 2005; 4: 1-9.
28. Lee SA, Lee CH, Jung WY, et al,. Paradoxical high signal intensity of hepatocellular carcinoma in the hepatobiliary phase of Gd-EOB-DTPA enhanced MRI: initial experience. Magn Reson Imaging 2011; 29: 83-90.
29. Kudo M,. Will Gd-EOB-MRI change the diagnostic algorithm in hepatocellular carcinoma? Oncology 2010; 78 (Suppl. 1): 87-93.
30. Narita M, Hatano E, Arizono S, et al,. Expression of OATP1B3 determines uptake of Gd-EOB-DTPA in hepatocellular carcinoma. J Gastroenterol 2009; 44: 793-8.
31. Tsuboyama T, Onishi H, Kim T, et al,. Hepatocellular carcinoma: hepatocyte-selective enhancement at gadoxetic acid-enhanced MR imaging-correlation with expression of sinusoidal and canalicular transporters and bile accumulation. Radiology 2010; 255: 824-33.
32. Nakashima Y, Nakashima O, Hsia CC, Kojiro M, Tabor E,. Vascularization of small hepatocellular carcinomas: correlation with differentiation. Liver 1999; 19: 12-8. (Pubitemid 29034105)
33. Bruix J, Sherman M,. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020-2.
34. Palmer WC, Patel T,. Are common factors involved in the pathogenesis of primary liver cancers? A meta-analysis of risk factors for intrahepatic cholangiocarcinoma. J Hepatol 2012; 57: 69-76.